How to appeal a denied claim for step-therapy (fail-first).
When a plan denies coverage on a fail-first, step-edit, or step-therapy rationale — a requirement that the patient try a preferred formulary drug, a conservative therapy, or a step-down agent before the prescribed drug — the appeal letter is built around the medical-necessity counter-argument framework, not the underlying diagnosis. The governing framework varies by plan type: the ACA Nondiscrimination obligation at 45 C.F.R. § 147.136 constrains discriminatory utilization management, the ERISA § 503 claims-procedure rule at 29 C.F.R. § 2560.503-1 governs the internal-appeal process for self-funded plans, and the per-state adverse-determination statute applies to fully-insured plans.
01 · Why carriers impose fail-first protocols
A step-therapy denial — and the medical-necessity counter-argument framework that defeats it.
Step-therapy is a utilization-management tool the plan imposes to drive utilization toward the cheapest clinically acceptable drug, and the denial of a step-therapy exception is one of the most common reasons a claim lands on an EOB with the reason code “step-therapy criteria not satisfied.” The dispute is not whether the prescribed drug is the right treatment for the diagnosis; it is whether the patient should be required to try a preferred step first, and whether the clinical exception request — supported by the prior-trial documentation, the documented contraindication, or the documented adverse event — warrants the exception.
The dispute the appeal letter must win is the medical-necessity exception, not the underlying coverage. The three named counter-arguments — inadequate trial response on the preferred step, documented contraindication to the preferred step, prior adverse event on the same drug class — each give the prescriber a clinically specific basis to bypass the fail-first protocol. Each is anchored in a different corner of the clinical record: a rheumatology dose-response diary, an allergy / contraindication notation, an emergency-department or hospitalization visit tied to the prior failed agent.
A well-built step-therapy exception appeal letter builds the case on the three counter-arguments above, attaches the supporting clinical documentation from the prior trial — not the original diagnosis justification — and frames the request as a clinical exception rather than a generic coverage dispute. The letter branches on whether the request is filed pre- (urgent, to start the prescribed therapy) or post-denial (internal appeal to overturn the EOB). The right framework on the federal side is the ACA Nondiscrimination rule at 45 C.F.R. § 147.136, the ERISA claims-procedure rule at 29 C.F.R. § 2560.503-1, or the per-state adverse-determination statute in the controlling jurisdiction.
01 · The three counter-arguments
The medical-necessity counter-argument framework — three named grounds the letter must build on.
01
Inadequate trial response
The patient has tried the preferred step agent on the plan’s formulary at a clinically adequate dose and for a clinically adequate duration, and the response was inadequate — the disease activity score, the lab markers, the patient-reported outcomes, or the imaging findings did not improve. The supporting documentation is the prescribing record, the labs drawn during the trial window, and the prescriber’s contemporaneous assessment of non-response. This is the most common counter-argument because the trial usually exists — the documentation just needs to be surfaced.
02
Documented contraindication
The preferred step agent carries a documented contraindication tied to the patient’s specific profile — a drug-drug interaction with a current medication, a comorbidity that elevates risk, a prior documented allergy on the chart, a black-box-warning trigger. The supporting documentation is the chart entry recording the contraindication (often from a routine medication reconciliation), the pharmacy record if any dispensation was attempted and reversed, and the prescriber’s clinical reasoning letter. This counter-argument does not require the patient to have failed the preferred step — the step is medically inappropriate.
03
Prior adverse event
The patient has experienced an adverse event either on the preferred step or on a same-class agent, with documentation in the chart, an emergency-department or urgent-care visit, a hospitalization, a register entry, or a discontinuity note in the prescriber’s record. The supporting documentation is the visit note, the discharge summary, the adverse-event report, or the chart entry the prescriber recorded when the agent was discontinued. This is the strongest counter-argument because it pairs the trial with a documented patient-safety event — and the Nondiscrimination framework explicitly contemplates prior adverse event as grounds to bypass the fail-first protocol.
01 · State-specific win points
Three jurisdictions with a step-therapy-specific lever on the EOB.
01
Illinois · 215 ILCS 125/5-6 psychiatric carve-out
IL psychiatric
The Illinois 2023 reform at 215 ILCS 125/5-6 provides a psychiatric carve-out from step-therapy protocols for prescribed psychotropic drugs — when the prescriber documents that an alternate agent would be clinically inappropriate, the plan must grant the exception on the same formulary step the enrollee would receive for a non-psychiatric condition. The appeal cites the carve-out directly, attaches the prescriber’s clinical letter, and frames the preservation of clinical stability on the prescribed agent as the documentary basis.
02
California · Knox-Keene §1368 step-therapy exception
CA Knox-Keene
California Knox-Keene licensees (Kaiser Permanente, Health Net, Blue Shield of California, Anthem Blue Cross CA products) are bound by Cal. Health & Safety Code § 1368 on the internal-appeal process, and by the Knox-Keene step-therapy exception framework for FDA-approved alternatives — when the prescribed drug is FDA-approved for the underlying condition and the prescriber documents a clinical reason the preferred step is not appropriate, the exception must be granted. Independent Medical Review (IMR) under § 1370.4 is the binding backstop within 180 days of the final internal denial.
03
New York · protocol-override pathway
NY override
New York fully-insured plans are bound by the NYDFS protocol-override pathway for prescribed-drug step-therapy denials — when the prescriber documents that the preferred-step agent is contraindicated, has caused an adverse event, or is reasonably expected to be ineffective based on the patient’s clinical profile, the plan must grant the exception within 72 hours (24 hours for urgent cases). The appeal cites the override pathway directly, attaches the prescriber’s clinical letter, and routes the dispute to NYDFS External Appeal under N.Y. Ins. Law § 4914 if the carrier refuses.
01 · ERISA procedural note
For self-funded ERISA plans — the arbitrary-denial standard at 29 C.F.R. § 2560.503-1.
Self-funded ERISA plans — typically larger employer group plans where the employer pays the claims rather than buying insurance from a carrier — run through the Department of Labor’s claims-procedure rule at 29 C.F.R. § 2560.503-1, implementing ERISA § 503 at 29 U.S.C. § 1133. The regulation requires the plan to give the claim a “full and fair review,” and the implementing language at § 2560.503-1(b)(1) prohibits denials that are “arbitrary and capricious.” A step-therapy denial that ignores documented prior failure on the same drug class, or that fails to name the clinical experts whose advice the plan relied on (the disclosure requirement under (j)(4)), does not survive the arbitrary-denial standard — and the member is entitled to the claims file under (m) without charge to surface the missing documentation.
The arbitrary-denial standard is the lever that distinguishes a denied claim from a denial the plan must defend. Specifically, the plan must show (i) that the step-therapy criteria it applied are written into the plan document and have been disclosed to the enrollee, (ii) that the clinical reasoning is on the record and authored by the named clinical experts under (j)(4), and (iii) that the conclusion follows from the evidence the plan considered. When any of those three are missing, the § 2560.503-1(b)(1) standard is not met, and the appeal letter frames the ask as a procedural-defect reversal under the federal claims-procedure rule — not as a re-litigation of the underlying medical-necessity determination.
01 · Worked sample paragraph
A first-person appeal paragraph that has already survived one round.
Below is a worked survivor-language paragraph — the kind of letter a member writes after a prior step-therapy exception denial has been re-denied on the same fail-first rationale. The voice is first-person, the evidence is attached, and the citations frame the request as a clinical-exception reversal rather than a re-argument of the underlying diagnosis.
Re: Second-stage internal appeal — step-therapy exception denied, EOB dated [DATE]
I am writing as the patient and as the party who has previously filed a first-stage appeal of this denial. The plan’s determination dated [DATE] cited step-therapy criteria not satisfied for the prescribed drug [DRUG NAME]; the prescriber’s clinical exception request was supported by documented prior failure on the preferred formulary agent, and supplied the chart note, the labs drawn during the prior trial, and the prescriber’s contemporaneous assessment of non-response. The first-stage appeal was denied without identifying the clinical experts whose advice the plan relied on — the disclosure required at 29 C.F.R. § 2560.503-1(j)(4) — and without citing any clinical-criteria document that distinguishes this patient’s documented response from the plan’s preferred-step requirement.
I am submitting additional clinical evidence to satisfy the full and fair review required under ERISA § 503 at 29 C.F.R. § 2560.503-1(b)(1). Specifically: (1) the prescriber’s clinical letter documenting the documented contraindication on the preferred-step agent, dated [DATE]; (2) the chart entry recording the patient’s adverse event within [DAYS] of starting the preferred step, with the emergency-department note attached; (3) the lab values drawn during the prior trial — [LAB, DATE, VALUE] — that establish inadequate trial response; and (4) the FDA-approved indication for [PRESCRIBED DRUG] that covers the prescribed clinical use. The ACA marketplace Nondiscrimination obligation at 45 C.F.R. § 147.136 directly constrains fail-first protocols when the patient has documented prior failure on the same drug class, and the determination on the desk does not engage that obligation on the clinical-criteria level.
I am requesting a reversal of the step-therapy exception denial, a determination that names the clinical experts under (j)(4), and disclosure of the claims file under (m) for any document the plan considered. If the plan maintains the denial, I am preserving the IRO right at 45 C.F.R. § 147.136(d) (where applicable), the state external-review channel in my jurisdiction, and the civil action under ERISA § 502(a) after exhaustion.
Cited: 45 C.F.R. § 147.136; 29 C.F.R. § 2560.503-1(b), (j)(4), (m); 29 U.S.C. § 1133.
Identifiers, member IDs, claim numbers, and street addresses in the sample paragraph above are placeholders — every name is invented, and only the controlling statute / CFR / USC citations are real (those are public law).
02 · Frequently asked
The Nondiscrimination, ERISA, and state frameworks that apply on a step-therapy denial.
Cited: step-therapy exception regulation · 29 C.F.R. § 2560.503-1 · ACA § 147.136 Nondiscrimination
Browse by state
Pick your state to see the appeal framework that applies.
Every state has a different agency, timeline, and binding external-review channel — start with yours.
03 · Submit the step-therapy denial
The same formulary exception, defended with the documented prior failure.
Upload the EOB or denial letter, answer the four short intake questions, and Denvow picks the Nondiscrimination framework under 45 C.F.R. § 147.136 or the ERISA § 503 procedure at 29 C.F.R. § 2560.503-1 — and the letter branches on whether you’re at the first-stage internal appeal or the second-stage external review.
Already in the intake? Pre-selected to “step-therapy failure” as the Segment-Denial-Reason — answer the rest and submit.
Other denial-reason pages
Denvow is template-and-tooling, not legal counsel. For denials that genuinely need litigation, an ERISA fiduciary complaint, or a state-court remedy, we recommend a licensed attorney in the relevant jurisdiction — and will say so when we see one.